SCHEDULE 13D/A: RA Capital Management Reaffirms Significant Stake in TYRA Biosciences with Updated SEC Filing

RA Capital Management, L.P. and its affiliates have filed an Amendment No. 4 to their Schedule 13D, confirming their continued beneficial ownership of 20.1% of TYRA Biosciences, Inc.'s common stock.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed Amendment No. 4 to their Schedule 13D regarding their beneficial ownership in TYRA Biosciences, Inc.
• The Reporting Persons collectively beneficially own an aggregate of 10,684,890 shares of TYRA Biosciences' common stock.
• This ownership represents 20.1% of the Issuer's common stock outstanding, based on 53,089,957 shares outstanding as of March 25, 2025.
• The holdings include shares held directly by RA Capital Healthcare Fund, L.P. (8,697,956 shares), a separately managed account (442,721 shares), and RA Capital Nexus Fund, L.P. (1,496,613 shares).
• The Reporting Persons also hold Pre-Funded Warrants exercisable for up to 1,538,457 shares and Exchange Warrants exercisable for up to 1,000,000 shares, both subject to a 19.99% beneficial ownership blocker.
• Additionally, 44,500 shares underlying vested stock options and 3,100 shares underlying stock options vesting within 60 days are held by Dr. Jake Simson for the benefit of RA Capital, with an exercise price of $15.94 per share.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a major institutional investor is maintaining a significant stake, which can be interpreted as continued confidence in the company. No negative information was disclosed.

Positives

• The continued significant beneficial ownership of 20.1% by RA Capital Management, a prominent healthcare-focused investment firm, signals ongoing confidence in TYRA Biosciences.
• The vesting of stock options for Dr. Jake Simson, benefiting RA Capital, indicates continued alignment of interests with the company's performance.

Future Outlook

The document primarily details current beneficial ownership and past/near-future vesting of stock options. It does not provide forward-looking statements or guidance regarding TYRA Biosciences' operational or financial performance.

Industry Context

This filing highlights the continued significant investment by RA Capital Management, a specialized healthcare and life sciences investment firm, in TYRA Biosciences, a company operating in the biotechnology sector. Such substantial stakes by dedicated industry investors are common and often viewed as a vote of confidence in the company's long-term prospects within the competitive biotech landscape.

Legal Proceedings

• None of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• None of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Stakeholder Impact

• Shareholders may view the continued significant investment by RA Capital Management as a positive signal of institutional confidence in TYRA Biosciences' future.
• The vesting stock options for Dr. Jake Simson, benefiting RA Capital, align the interests of a key individual associated with the investor with the company's performance.

Next Steps

• Continued vesting of stock options for Dr. Jake Simson, with 1,550 shares vesting on April 29, 2025, and another 1,550 shares vesting on May 29, 2025.

Key Dates

Keywords

TYRA Biosciences, RA Capital Management, Schedule 13D, Beneficial Ownership, Common Stock, Biotechnology, Investment Firm, SEC Filing, Warrants, Stock Options